Intracranial Arterial Stenosis Clinical Trial
Intracranial arterial prominent stenosis (IAPS) is one of main cause of stroke especially in
Asia. Although antiplatelet aggregative or anticoagulant agent and even surgical operation
are used to treat patients with IAPS, the incidence of stroke occurrence still remains high.
In addition, symptomatic IAPS most common cause continuous deterioration, thus, increase the
incidence of stroke. Therefore, there is a good method to reduce the inceidence of stroke
that is to prevent the progressive deterioration of IAPS.
Huang-Chi-Wu-Wu-Tang is made of Astrgalus membranaceus (Fisch.) Gge , Paeonia lactiflora
Pall , Cinnamom Twig , Zingiber officinale Rose , Ziziphus jujube Mill , and can treat
hemiplegia in the traditional Chinese medicine writings. Astragaloside IV is a component of
Astrgalus membranaceus, may reduce th cerebral infarction area in middle cerebral arterial
occlusion mice. The investigators previous studies have known that paeoniflorin that a
component of Paeonia lactiflora Pall can decrease the cerebral infarction area and
neurological deficit in middle cerebral arterial occlusion rats. Therefore, the purpose of
the present study was to investigate the effect of Huang-Chi-Wu-Wu-Tang on patients with
IAPS.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01819597 -
Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis
|
N/A | |
| Recruiting |
NCT05844176 -
Intracranial Arterial Stenosis in Young Patients
|
||
| Enrolling by invitation |
NCT04240119 -
Angiogenic Markers in Cerebrovascular Disease (ANFIS)
|
||
| Completed |
NCT01570231 -
Feasibility, Safety and Efficacy of Remote Ischemic Preconditioning for Symptomatic Intracranial Arterial Stenosis in Octogenarians
|
Phase 1 | |
| Completed |
NCT02041117 -
Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging
|
Phase 4 |